|Drug General Information||Top|
|Indication||Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19]||Phase 2|||
|Non-small-cell lung cancer [ICD-11: 2C25.Y]||Phase 2|||
|Target and Pathway||Top|
|Target(s)||Epidermal growth factor-like protein 7 (EGFL7)||Target Info||Modulator|||
|REF 1||ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.|
|REF 2||A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614.|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.